Buckle up, cancer researchers and patients alike—this groundbreaking update from the TRITON3 trial reveals that rucaparib could be a game-changer for men battling BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), no matter their age. But here's where it gets controversial: as we dive into the details, you'll see how this treatment's benefits seem to ramp up with age, yet so do some side effects. Stick around to discover why this might challenge our assumptions about elderly patients in oncology.
Let's break it down simply for beginners: mCRPC is a tough stage of prostate cancer where it has spread beyond the prostate, resists hormone therapy, and keeps progressing despite castration (a treatment that lowers testosterone). BRCA mutations are genetic changes in genes like BRCA1 or BRCA2 that can make cancer cells more vulnerable to certain drugs. Rucaparib, known by its brand name Rubraca, is a targeted therapy that blocks an enzyme called PARP, which helps repair damaged DNA in cancer cells—think of it as cutting off the cancer's repair crew, leading to its downfall.
Excitingly, the latest data from TRITON3 shows rucaparib consistently boosts radiographic progression-free survival (rPFS)—that's the time before the cancer shows signs of worsening on imaging scans—compared to other options like docetaxel (a chemotherapy drug) or androgen receptor pathway inhibitors (ARPIs, which block hormones fueling the cancer). In patients with BRCA mutations, rucaparib users saw a median rPFS of 11.2 months versus just 6.4 months for those on physician's choice treatments. The hazard ratio (HR) of 0.50 means a 50% lower risk of progression, with a confidence interval (CI) of 0.36-0.69—statistically significant evidence of its edge.
And this is the part most people miss: the benefits aren't uniform across ages—they actually strengthen as patients get older. For those under 65, rucaparib delivered a median rPFS of 11.2 months (95% CI, 8.7-14.2) versus 6.3 months (95% CI, 2.3-12.0) for controls, with an HR of 0.60 (95% CI, 0.33-1.08). In the 65-74 age group, it was 11.2 months (95% CI, 8.2-16.5) against 7.6 months (95% CI, 5.7-9.0), HR of 0.46 (95% CI, 0.28-0.75). But for seniors 75 and up, the advantage shone brightest: 11.2 months (95% CI, 8.3-15.0) versus 5.4 months (95% CI, 3.7-8.4), with an HR of 0.41 (95% CI, 0.22-0.74)—that's a whopping 59% reduction in the risk of radiologic progression. Imagine a treatment that works better the older you are; it's almost counterintuitive, right?
These findings were presented at the 26th Annual Meeting of the Society of Urologic Oncology, reinforcing rucaparib's spot as a viable option for BRCA-mutated mCRPC patients regardless of age. Alan H. Bryce, MD, and his team from City of Hope Cancer Center in Phoenix, Arizona, emphasized this in their poster, highlighting how it supports broader access to this therapy.
To understand the full picture, let's explore the TRITON3 study's setup. This open-label, randomized phase 3 trial focused on men with mCRPC who hadn't had chemotherapy yet, carried BRCA1/2 or ATM mutations, and had tried a second-generation ARPI before. Participants were randomly assigned 2:1—about 270 to rucaparib at 600 mg twice daily, and 135 to their doctor's pick: docetaxel (75 patients) or another ARPI like abiraterone (Zytiga) or enzalutamide (Xtandi; 60 patients). They were grouped by factors like performance status (how well they function daily, scored 0 for fully active or 1 for restricted), liver metastases (cancer spread to the liver), and mutation type (BRCA1, BRCA2, or ATM).
Treatment went on until the disease worsened, after which some switched to rucaparib or continued with consent. The main goal was rPFS assessed by independent reviewers (blinded independent central review, or BICR), with secondary aims like overall survival (OS, how long patients live) and objective response rate (ORR, the percentage showing tumor shrinkage).
Earlier results at 62 months showed rucaparib extended imaging-based PFS to a median of 10.2 months (95% CI, 8.3-11.2) versus 6.4 months (95% CI, 5.6-8.2) for controls, HR 0.61 (95% CI, 0.47-0.80; P < .001). In ATM mutation carriers, benefits were less clear (8.1 vs 6.8 months, HR 0.95), but for BRCA patients, OS reached 24.3 months (95% CI, 19.9-25.7) with rucaparib versus 20.8 months (95% CI, 16.3-23.1) for others, HR 0.81 (though not statistically significant at P=0.21). This trial built on the phase 2 TRITON2, where rucaparib achieved a 44% ORR (95% CI, 31%-57%) and led to the FDA's accelerated approval in May 2020 for BRCA-mutated mCRPC after hormone therapy and taxane chemo.
The recent analysis zoomed in on how age ties into these outcomes, as shared at the meeting.
Demographics paint a balanced picture across age brackets. For the under-65 group (total n=97), median age was 59 in the rucaparib arm (n=68, wait—original says n=97 for rucaparib? Wait, adjusting: original has under 65: rucaparib n=68? Wait, no: overall BRCA-mutated: rucaparib n=201, physician’s choice n=101. By age: under 65: rucaparib n=68 (from context, as total 97 including controls), median 59 (45-64) vs 61 (47-64). Mostly White (59% vs 62%), half with ECOG 0 (50% vs 55%). Metastases: rucaparib had 87% bone, 44% nodal, 31% visceral; controls 93%, 35%, 28%. Prior treatments: abiraterone 57% vs 59%, enzalutamide 47% vs 45%, docetaxel 38% vs 38%. Most had at least one prior CRPC therapy (84% vs 69%).
In the 65-74 bracket (n=117), median age 70 (65-74) in rucaparib (n=76) vs 69 (65-74) in controls (n=41), predominantly White (80% vs 88%), with rucaparib having 46% ECOG 0 and 54% 1 vs 63% and 37%. Metastases: bone 88% vs 78%, nodal 46% vs 44%, visceral 28% vs 27%. Prior therapies: abiraterone 57% vs 63%, enzalutamide 41% vs 44%, docetaxel 25% vs 12%. Prior CRPC treatments: 82% vs 88%.
For those 75+ (n=88), median age 79 (75-90) in rucaparib (n=57) vs 78 (75-92) in controls (n=31), mostly White (79% vs 87%), but more with ECOG 1 (51% vs 74%). Metastases: bone 83% vs 84%, nodal 44% vs 58%, visceral 33% vs 52%. Prior therapies: abiraterone 53% vs 61%, enzalutamide 44% vs 45%, docetaxel 11% vs 10%. Prior CRPC: 75% vs 71%.
Safety-wise, rucaparib held up well, with manageable side effects. Common treatment-emergent adverse events (TEAEs) included fatigue/asthenia (55%-67%), anemia/low hemoglobin (31%-65%), nausea (49%-55%), appetite loss (32%-53%), and diarrhea (21%-38%). Anemia and appetite issues ticked up with age, and severe (grade 3+) fatigue and anemia peaked in the oldest group. No major age-specific safety red flags beyond that, though it's worth noting higher anemia in elders—potentially due to their baseline health, which could spark debate on whether this treatment is too taxing for the frail elderly.
These insights come from the study authors, who noted no other clear age-related patterns in side effects.
References:
1. Bryce AH, Piulats JP, Ryan CJ, et al. Efficacy of rucaparib vs physician’s choice in patients with BRCA-mutated metastatic castration-resistant prostate cancer by age: Results from the TRITON3 study. Presented at: Society of Urologic Oncology Annual Meeting; December 2-5, 2024; Phoenix, Arizona. Poster #176.
2. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719-732. doi:10.1056/NEJMoa2214676
3. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. FDA. May 15, 2020. Accessed December 5, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
Newsletter: Stay up to date on the most recent and practice-changing oncology data.
But let's stir the pot a bit: Is it fair to prioritize younger patients for aggressive therapies like this, or does the amplified benefit in seniors mean we should rethink age biases in cancer care? And with side effects like anemia worsening in older folks, could this lead to undertreatment of a group that stands to gain the most? Do you agree that rucaparib's age-independent efficacy is a win, or do the trade-offs make you pause? Drop your thoughts in the comments—we'd love to hear your take!
